AbstractWe report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight was 65.7 kg. The median nucleated cell dose infused was 2.07 × 107/kg. Eight of the 13 patients demonstrated donor chimerism between 4 weeks and 6 months, and subsequent conversion to full donor chimerism was achieved in 5 patients. Three patients were alive and free of disease at 158 to 1054 days, with a median survival of 288 days after transplantation. The 100-day event-free survival is 69%, and overall survival is 77%. At 1 year, the event-free and overall survival was 43%. Tr...
AbstractUmbilical cord blood (UBC) stem cells are a useful stem cell source for patients without mat...
AbstractAlthough allogeneic stem cell transplantation can cure patients with hematologic malignancie...
Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical compone...
AbstractWe report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablati...
AbstractUnrelated umbilical cord blood (UCB) transplantation has recently been explored in an increa...
AbstractSince January 1996, we have administered myeloablative therapy followed by infusion of unrel...
Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients wit...
AbstractNonmyeloablative hematopoietic cell transplantation (HCT) has been used to treat patients wi...
AbstractThe Cord Blood Transplantation study group conducted a prospective study of unrelated cord b...
Clinical studies focused on disease-specific outcomes of cord blood transplant (CBT) from unrelated ...
The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic ...
The Cord Blood Transplantation study group conducted a prospective study of unrelated cord blood tra...
AbstractWe analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
Double umbilical cord blood transplantation (UCBT) with a reduced-intensity conditioning regimen is ...
AbstractUmbilical cord blood (UBC) stem cells are a useful stem cell source for patients without mat...
AbstractAlthough allogeneic stem cell transplantation can cure patients with hematologic malignancie...
Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical compone...
AbstractWe report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablati...
AbstractUnrelated umbilical cord blood (UCB) transplantation has recently been explored in an increa...
AbstractSince January 1996, we have administered myeloablative therapy followed by infusion of unrel...
Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients wit...
AbstractNonmyeloablative hematopoietic cell transplantation (HCT) has been used to treat patients wi...
AbstractThe Cord Blood Transplantation study group conducted a prospective study of unrelated cord b...
Clinical studies focused on disease-specific outcomes of cord blood transplant (CBT) from unrelated ...
The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic ...
The Cord Blood Transplantation study group conducted a prospective study of unrelated cord blood tra...
AbstractWe analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients...
Cord blood transplantation (CB-T) is increasingly used as a treatment alternative for hematologic ma...
Double umbilical cord blood transplantation (UCBT) with a reduced-intensity conditioning regimen is ...
AbstractUmbilical cord blood (UBC) stem cells are a useful stem cell source for patients without mat...
AbstractAlthough allogeneic stem cell transplantation can cure patients with hematologic malignancie...
Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical compone...